Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.41 |
| ▸ | F2 | P00734 | 10/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 9/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 9/20 | 0.41 |
| ▸ | PLG | P00747 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084008 | 0.98 | F10 (0.43) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7087237 | 0.96 | F10 (0.44) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7088654 | 0.93 | F10 (0.44) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7088648 | 0.91 | F10 (0.48) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7087643 | 0.91 | F10 (0.48) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7084357 | 0.91 | F10 (0.47) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7084016 | 0.90 | F10 (0.43) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7088626 | 0.90 | F10 (0.50) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7067839 | 0.90 | PRSS1 (0.45) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7087041 | 0.90 | F10 (0.46) | F10PRSS1F2PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199544-A1 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | claimed |
| US-20030199542-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-10-23 | — | — | US | claimed |
| US-20030199544-A1 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| US-20030199542-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199542-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | F10 1541/4885PRSS1 481/4885F2 340/4885 |
| US-20030199544-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | F10 1541/4885PRSS1 481/4885F2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.